Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2013
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneM Gnant, M Filipits, R Greil, et al.
ESMO Open|March 27, 2026
Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort studyF Moik, F Huemer, B Doleschal, et al.
Leukemia Research|March 7, 2003
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)T Kühr, S Burgstaller, U Apfelbeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12M Gnant, B Mlineritsch, H Stoeger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2001
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy aloneE Dühmke, J Franklin, M Pfreundschuh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trialM Sieber, H Tesch, B Pfistner, et al.
Frontiers in Oncology|October 22, 2025
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinomaJ-P Machiels, Y Tao, L Licitra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trialM Dugo, C-S Huang, D Egle, et al.
ESMO Open|December 23, 2022
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study GroupS P Gampenrieder, V Dezentjé, M Lambertini, et al.
Pageof 12